Summary
The U.S. FDA’s panel of independent advisers on Thursday recommended against GSK’s blood cancer drug Blenrep, citing concerns about previously documented risks of eye-related side effects, sending the British drugmaker’s U.
Source: Reuters on MSN.com
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
